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Abstract.	
The	emergence	of	complement	as	an	important	player	in	normal	brain	development	and	
pathological	remodelling	has	come	as	a	major	surprise	to	most	scientists	working	in	neuroscience	
and	almost	all	those	working	in	complement.	That	a	system,	evolved	to	protect	the	host	against	
infection,	should	have	these	unanticipated	roles	has	forced	a	rethink	about	what	complement	might	
be	doing	in	the	brain	in	health	and	disease,	where	it	is	coming	from,	and	whether	we	can,	or	indeed	
should,	manipulate	complement	in	the	brain	to	improve	function	or	restore	homeostasis.		
Complement	has	been	implicated	in	diverse	neurological	and	neuropsychiatric	diseases	well-
reviewed	elsewhere,	from	depression	through	epilepsy	to	demyelination	and	dementia;	in	most	
complement	drives	inflammation	to	exacerbate	the	disease.		Here	I	will	focus	on	just	one	disease,	
the	most	common	cause	of	dementia,	Alzheimer’s	disease.		I	will	briefly	review	the	current	
understanding	of	what	complement	does	in	the	normal	brain,	noting,	in	particular,	the	many	gaps	in	
understanding,	then	describe	how	complement	may	influence	the	genesis	and	progression	of	
pathology	in	Alzheimer’s	disease.	Finally,	I	will	discuss	the	problems	and	pitfalls	of	therapeutic	
inhibition	of	complement	in	the	Alzheimer	brain.	
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The	brain	as	an	island	apart.	
The	brain	is	without	doubt	a	special	organ,	weight	for	weight	the	most	energy-hungry,	and	isolated	
from	peripheral	insults	by	an	intelligent	barrier	that	dictates	which	substances	enter	and	leave	the	
brain	parenchyma.	This	blood-brain	barrier	(BBB)	comprises	a	collaboration	between	the	specialised	
brain	endothelium,	vascular	pericytes,	perivascular	glia	and	neurones,	together	forming	a	highly	
selective	defensive	wall	to	conserve	brain	homeostasis	[1].	In	the	healthy	brain,	cell	transit	across	
this	wall	is	extremely	restricted;	hence,	peripheral	immune	cells	are	essentially	excluded	and	transit	
of	the	majority	of	proteins	from	plasma,	including	complement	proteins,	limited	such	that	levels	in	
the	brain	parenchyma	and	cerebrospinal	fluid	(CSF)	are	typically	between	1%	and	0.1%	those	in	
plasma.	A	few	proteins	buck	this	trend	either	because	they	are	actively	transported	across	the	BBB	
through	receptor-mediated	transcytosis	(for	example,	transferrin)	or	are	synthesised	in	the	brain.		
Important	as	the	BBB	is	in	maintaining	homeostasis	and	protecting	the	brain	from	external	and	
intrinsic	insults,	it	is	by	no	means	a	perfect	barrier.	Even	in	the	healthy	brain,	there	are	regions	
where	the	BBB	is	compromised,	particularly	in	the	aged	normal	brain	where	evidence	of	barrier	loss	
in	and	around	the	hippocampus	has	been	described	[2].	Whether	these	chinks	in	the	brain’s	armour	
are	sufficient	to	allow	complement	proteins	access	is	untested.		Almost	any	disease	that	affects	the	
brain,	and	many	systemic	diseases,	can	trigger	BBB	leakage	in	various	degrees.	Numerous	mediators	
have	been	implicated,	including	reactive	oxygen	species	and	activation	of	tissue	metalloproteinases,	
but	the	dominant	pathway	to	BBB	breakdown	is	inflammation	–	central	or	systemic	[3,4].	
Neurodegenerative	and	neuroinflammatory	diseases	are	associated	with	disruption	of	the	BBB,	a	
consequence	of	endothelial	leakage	and	inflammatory	cell	infiltration	[5].	In	multiple	sclerosis	(MS),	
a	strongly	inflammatory	disease,	individual	areas	of	BBB	breakdown	are	obvious	and	routinely	
imaged	in	gadolinium-enhanced	MRI	scans	[6],	but	in	slow-burn,	chronic	inflammatory	diseases	like	
Alzheimer’s	disease	(AD),	BBB	impairment	may	be	much	more	subtle,	localised	to	areas	of	pathology	
and	affecting	specific	transport	processes	–	for	example,	transport	of	amyloid	β	[7].		Even	in	
neuropsychiatric	diseases,	BBB	impairment	may	occur	and	be	a	key	driver	of	disease	–	for	example,	
in	schizophrenia	there	is	growing	evidence	that	BBB	leak	contributes	to	perpetuation	of	the	
pathology	[8].	Systemic	inflammation,	for	example,	as	a	result	of	infections	or	injuries,	can	
independently	cause	disruption	of	the	BBB	and	exacerbate	barrier	failure,	perhaps	explaining	the	
well-documented	impact	of	systemic	illness	on	cognitive	state	in	AD	[4].	Indeed,	in	a	mouse	model	of	
AD	the	BBB	was	sensitised	to	disruption	caused	by	low-dose	lipopolysaccharide	administration	[9].	
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Where	does	the	healthy	brain’s	complement	come	from?	
Complement	provides	an	important	innate	immune	defence	against	infection	and	essential	
contribution	to	effective	garbage	disposal	in	tissues;	it	is	likely	that	complement	plays	these	same	
homeostatic	roles	in	the	brain	–	but	what	is	the	source?	The	dominant	source	for	most	complement	
proteins	in	plasma	(and	tissues)	is	the	liver;	the	exceptions	to	this	rule	are	C1q,	properdin	and	C7,	
synthesised	predominantly	in	leukocytes,	and	factor	D	made	in	adipose	tissue	[10,11].	With	these	
exceptions,	in	most	circumstances	hepatic-derived	complement	proteins	secreted	into	plasma	and	
leaching	into	tissues	are	the	mediators	of	complement	immune	defence.	However,	the	list	of	sites	of	
extrahepatic	synthesis	of	complement	proteins	has	grown	steadily	and	it	is	now	clear	that	many	
organs	and	tissues	can	make	most	or	all	complement	proteins	locally.	In	most	cases	this	is	at	
cottage-industry	scale	when	compared	to	the	liver	mega-factory,	routinely	churning	out	grams	per	
day	of	C3,	and	much	more	in	response	to	acute	phase	triggers;	however,	in	some	circumstances	this	
local	synthesis	can	be	very	significant.	Indeed,	studies	in	transplant	recipients	have	suggested	that	
around	10%	of	plasma	complement	proteins	are	derived	from	the	various	extra-hepatic	sources	[12].	
The	largest	organ	contributor	to	this	extra-hepatic	pool	is	likely	the	kidney;	transplant	studies	have	
shown	that	a	single	donor	kidney	can	contribute	~5%	of	plasma	C3	[13].	Locally	produced	
complement	may	contribute	to	the	circulating	pool	but,	much	more	importantly,	may	provide	local	
immune	defence	or	drive	pathology	in	that	organ.		In	the	kidney,	this	role	for	local	complement	has	
been	abundantly	demonstrated	in	experimental	disease	models	by	transplantation	studies	utilising	
complement	deficient	organs	and	recipients.			
In	contrast	to	this	clear	evidence	for	renal	complement	synthesis,	evidence	for	local	synthesis	of	
complement	in	the	healthy	brain	is	very	limited	–	perhaps	because	brain	transplantation	remains	
unmastered!		The	“protected”	status	of	the	brain,	described	above,	implies	that	most	plasma	
proteins	are	excluded	from	the	healthy	brain.	The	intact	blood-brain	barrier	(BBB)	will	restrict	or	
prevent	access	of	complement	proteins	from	the	periphery;	hence,	local	production	may	be	
particularly	important	for	innate	immune	defence	in	the	healthy	brain.		There	have	been	numerous	
studies	of	complement	protein	expression	in	isolated	brain	cells	and	brain-derived	cell	lines.	These	
data	demonstrate	that	cell	lines	of	microglial,	astroglial	and	even	neuronal	origin	can	synthesise	and	
secrete	most	or	all	complement	proteins	when	appropriately	stimulated	in	vitro	[10,11].	The	
relevance	of	these	very	artificial	models	to	the	situation	in	the	normal	healthy	brain	is	tenuous	at	
best.	A	handful	of	reports	have	described	the	identification	of	complement	proteins	or,	critically	in	
building	the	case	for	local	production,	message	encoding	complement	proteins,	in	human	brain	
tissue	but	mostly	in	pathological	brain	from	inflammatory	or	degenerative	cases	[14-16].	One	report	
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compared	expression	of	mRNAs	for	C1q,	C3	and	C4	in	healthy	and	Alzheimer’s	disease	(AD)	brain	
[17].	All	three	were	expressed	in	healthy	brain	and	levels	of	message	were	three-fold	higher	in	AD	
brain.	Others	described	message	encoding	C1	subunits,	C1	inhibitor	(C1inh),	C3	and	C4	in	healthy	
brain	with	expression	increased	2-5-fold	in	Huntington’s	disease	(HD)	brain	[18].		Expression	of	
complement	regulators	is	low	in	the	normal	brain	compared	to	other	organs,	with	neurones	
particularly	poorly	endowed;	in	contrast,	complement	receptors,	including	the	anaphylatoxin	
receptors,	are	expressed	on	glia	and	neurones,	demonstrating	a	capacity	to	respond	to	local	
complement	activation	[19,20].			
Overall,	a	picture	emerges	of	a	low-complement	environment	in	the	healthy	brain	with	little	or	no	
ingress	from	the	circulation	and	minimal	local	biosynthesis;	in	this	environment,	brain	cells	are	
poorly	protected	from	complement	because	they	express	relatively	low	levels	of	defence	proteins,	
but,	through	expression	of	complement	regulators,	retain	the	capacity	to	respond	to	any	
complement	activation	that	does	occur	locally.	In	the	inflamed	or	injured	brain,	the	situation	is	likely	
very	different.	
	
What’s	complement	doing	in	the	normal	brain?	Keeping	house	and	tending	connections.		
In	the	periphery,	complement	functions	to	protect	against	infections	and	dispose	of	garbage	(Figure	
1A).	In	the	brain,	complement	likely	performs	these	same	roles	but	also	contributes	to	maintenance	
and	homeostasis	in	other	ways.		Clues	to	these	other	roles	have	emerged	from	detailed	analyses	of	
complement-deficient	mice.		In	C3-deficient	mice,	removal	of	synapses	from	damaged	neurones	is	
impaired,	synapse	number	is	increased	and	cognitive	performance	is	enhanced	[21,22].	Ageing-
associated	loss	of	synapses	in	the	hippocampus	was	also	reduced	in	C3-deficient	mice	and	
associated	with	improved	learning	and	memory,	suggesting	that	complement	is	bad	for	synapse	
health	in	ageing	[23].		However,	too	many	synapses	is	not	entirely	a	good	thing:	C1q-deficient	mice	
showed	defective	synaptic	pruning,	resulting	in	an	over-connected	brain	and	a	remarkable	
susceptibility	to	epileptic	events	[24-26].		Together,	the	data	demonstrate	an	essential	homeostatic	
role	of	complement	activation	in	the	normal	brain	to	tag	damaged	or	effete	synapses	and	facilitate	
the	continuing	re-wiring	that	occurs	in	development	and	throughout	life	as	part	of	brain	plasticity.	
Several	neurodevelopmental	and	neurodegenerative	diseases,	including	schizophrenia	and	AD,	have	
been	associated	with	abnormal	synaptic	pruning;	the	relevance	of	complement	dysregulation	in	
these	diseases	is	the	subject	of	current	research	and	thoroughly	reviewed	elsewhere	[27].			
What’s	so	special	about	the	brain?	Demolishing	the	blood-brain	barrier		
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Although	the	BBB	is	not	absolute,	and	some	macromolecules	by-pass	the	barriers	[28],	complement	
proteins	without	exception	cannot	penetrate	to	reach	the	brain	parenchyma	unless	BBB	integrity	is	
disrupted.	Almost	any	disturbance	of	brain	homeostasis	–	infection,	injury,	infarct	or	inflammation	–	
can	bring	down	to	the	barrier	to	some	degree.	As	noted	above,	systemic	factors,	including	infections	
and	inflammation,	can	also	compromise	the	BBB	[29].		Whatever	the	trigger,	barrier	disruption	
allows	ingress	of	normally	excluded	proteins,	including	complement	proteins,	into	the	parenchyma	
surrounding	the	initiating	damage.	Injured,	ischaemic,	apoptotic	or	foreign	surfaces	will	trigger	
activation	of	complement,	causing	further	damage,	particularly	on	cells	poorly	protected	by	
regulators,	and	driving	a	vicious	cycle	of	inflammation,	further	BBB	disruption	and	influx	of	more	
complement	proteins	to	feed	the	flames	(Figure	1).		This	scenario	is	most	clearly	enacted	in	the	case	
of	ischaemic	stroke	where	reperfusion	of	the	ischaemic	tissue	causes	local	inflammation	and	loss	of	
BBB	integrity;	influx	of	complement	proteins	and	activation	around	the	infarct	causes	lesion	
expansion.	This	critical	role	of	complement	is	clearly	demonstrated	in	stroke	models	where	
complement	deficiency	or	anti-complement	drugs	markedly	reduce	lesion	size	[30,31].				
In	many	other	brain	pathologies,	evidence	that	complement	is	activated	at	some	stage	in	the	disease	
process	is	clear.	In	MS,	complement	activation	products	are	abundant	in	and	around	lesions,	likely	
reflecting	BBB	breakdown	and	influx,	although	increased	local	biosynthesis	may	also	contribute	
[32,33].	In	AD,	complement	activation	products	richly	decorate	plaques	and	tangles	[34]	(Figure	2).		
Of	course,	association	does	not	imply	causation;	the	presence	of	complement	activation	products	in	
areas	of	pathology	in	advanced	disease	could	represent	a	secondary	phenomenon	unrelated	to	the	
disease	process.	However,	taken	together	with	other	lines	of	evidence,	a	strong	case	can	be	
developed	for	a	causal	role	of	complement	in	many	brain	diseases.		The	case	for	AD	is	expanded	
below.	
Complement	in	neurodegeneration	
Neurodegenerative	diseases	are	defined	by	the	progressive	loss	of	neurons	and	so	have	been	
considered	incurable	and	untreatable.	Mitochondrial	dysfunction,	protein	miss-folding,	and	other	
forms	of	systems	failure	underpin	the	pathology	in	most	neurodegenerative	diseases.	Global	
neurodegeneration	causes	progressive	dementia,	as	seen	in	AD.		In	Parkinson’s	disease,	the	earliest	
pathology	affects	the	substantia	nigra	leading	to	the	typical	movement	disorder,	but	global	disease	
and	dementia	follows.	In	amyotrophic	lateral	sclerosis	(ALS)	and	other	motor	neurone	diseases,	
motor	neurones	are	lost	selectively	leading	to	increasing	disability	but	with	retention	of	cognitive	
function	(as	Stephen	Hawking	amply	demonstrates).		
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AD	is	the	commonest	cause	of	dementia	with	over	850,000	sufferers	in	the	UK	alone,	over	50	million	
globally	and	an	economic	cost	expected	to	hit	$1	trillion	in	2018	(statistics	from	Alzheimer’s	
Research	UK;	http://www.alzheimersresearchuk.org/).	Incidence	is	increasing	as	the	population	
ages,	signalling	a	global	epidemic	of	unparalleled	magnitude.	From	its	first	description	in	1906	until	
very	recent	times,	AD	was	considered	a	purely	degenerative	disease,	characterised	by	progressive	
loss	of	neurones	and	brain	atrophy	[35].		The	first	suggestions	that	AD	might	have	an	inflammatory	
component	emerged	in	the	1980s;	acute	phase	reactants	were	shown	to	be	increased	in	plasma	
from	AD	patients	compared	with	controls,	glial	cells	in	AD	brain	showed	changes	associated	with	
inflammation,	and	prior	use	of	non-steroidal	anti-inflammatory	drugs	(NSAIDs)	for	unrelated	
conditions	protected	against	AD,	findings	replicated	in	animal	models	[36].	A	review	published	in	
1994	concluded	that	the	evidence	studies	implicating	inflammation	in	AD	was	strong	and	made	the	
case	for	formal	trials	of	anti-inflammatory	therapies	[37];	surprisingly,	more	than	twenty	years	later,	
there	have	still	been	no	large	trials	of	the	impact	of	NSAIDs	or	other	anti-inflammatory	agents	
administered	early	in	the	disease	process	on	the	course	of	AD.	Importantly,	inflammatory	activation	
of	microglia	and	astrocytes	is	now	recognised	as	a	key	marker	of	the	AD	brain	[38,39].		
As	evidence	accumulates	that	AD	is	an	inflammatory	disease	associated	with	some	degree	of	BBB	
breakdown,	it	becomes	an	inevitability	that	complement	will	play	a	role	in	the	pathology.	
Complement	is	a	strongly	pro-inflammatory	system	with	the	capacity	to	cause	damage	to	self	both	
indirectly	through	recruitment	and	activation	of	immune	cells	and	directly	through	its	cytotoxic	
effector	the	membrane	attack	complex	(MAC).	Complement	causes	pathology	when	regulation	fails;	
this	leads	to	excessive	and	widespread	activation,	driving	inflammation	and	tissue	damage.		Acute	
dysregulation	can	cause	overwhelming	injury,	as	seen	in	sepsis;	in	most	diseases,	chronic,	low-grade	
dysregulation	occurs	that	leads	to	the	accumulation	of	damage	over	time.		
The	nervous	system	is	particularly	susceptible	to	damage	caused	by	complement	dysregulation	
because	its	resident	cells,	neurones	and	glia,	are	poorly	protected	from	the	products	of	complement	
injury	[19,20,40].	Degrees	of	dysregulation	that	might	be	tolerated	in	other	tissues	thus	cause	
damage	in	the	brain	and	other	parts	of	the	nervous	system.	Potential	triggers	for	complement	
dysregulation	in	neurodegeneration	are	legion.	Autoantibodies	can	initiate	the	classical	pathway;	
protein	aggregates,	damaged	cells,	exposed	myelin	antigens	or	pathogens	can	trigger	multiple	
activation	pathways;	trauma	or	anoxia	activates	complement	locally	or	globally	(Figure	1).	This	
perfect	storm	can	drive	a	vicious	cycle	of	complement	activation	and	inflammation;	restoring	
complement	homeostasis	may	break	this	cycle	and	ameliorate	disease.			
Immunohistochemistry	implicates	complement	in	AD.				
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A	role	for	complement	as	a	driver	of	inflammation	in	the	AD	brain	first	emerged	in	the	1980s,	based	
upon	guilt	by	association;	immunohistochemistry	in	late-stage	AD	brain	demonstrated	that	the	
prototypical	lesions,	amyloid	plaques,	were	richly	decorated	with	complement	proteins	[41-44].	
Early	components	of	the	classical	pathway	(C1q,	C4,	C1inh)	were	particularly	abundant,	but	
detection	of	terminal	pathway	proteins	was	inconsistent	[45,46].		Importantly,	staining	with	specific	
antibodies	demonstrated	the	presence	of	complement	activation	products	including	C3b/iC3b	and	
the	terminal	complement	complex	(TCC),	confirming	that	the	complement	system	was	activated	in	
and	around	plaques	in	AD	(Figure	2).	Of	particular	note,	dystrophic	neurites	were	TCC/MAC-positive,	
suggesting	that	MAC	may	cause	direct	damage,	contributing	to	neuritic	dystrophy	and	neuronal	loss	
in	AD	brain	[47].	Of	course,	immunohistochemistry	in	post-mortem	brain	only	provides	information	
on	end-stage	disease	and	gives	no	clues	as	to	whether	complement	activation	occurs	early	in	the	
disease	process.	In	unpublished	studies,	we	examined	complement	protein	deposition	in	post-
mortem	brain	at	different	stages	of	AD,	from	the	earliest	(Braak	stage	I)	to	late	(Braak	stage	V),	and	
showed	that	even	in	early	disease,	complement	was	present	and	activated	in	areas	of	pathology.		
C1q	appears	to	be	an	important	marker	of	neurodegeneration	in	both	rodents	and	man;	however,	
C1q	staining	is	also	associated	with	brain	ageing	in	the	absence	of	dementia	[48].	C1q	staining	also	
strongly	correlated	with	pathology	in	MS	brain,	with	predominant	staining	for	both	C1q	and	the	
regulator	C1inh	on	neurones	[49].	Taken	together,	the	evidence	suggests	that	complement	is	
activated	in	areas	of	pathology	at	all	stages	of	neurodegeneration.	As	noted	above	the	source	of	
complement	within	the	brain	in	health	and	disease	is	debated,	but	there	is	considerable	evidence	
supporting	local	synthesis	of	complement	proteins	in	the	brain	in	neurodegeneration.		In	MS,	glia	
and	neurones	generate	C1q,	C3	and	other	key	components	[49],	and	it	has	been	reported	that	
cerebral	vascular	endothelial	cells	can	make	all	complement	proteins	[50].	These	latter	authors	
showed	that	endothelial	complement	biosynthesis	was	increased	by	exposure	ex	vivo	to	aggregated	
Aβ,	and	suggested	a	role	for	endothelial	complement	in	forming	the	characteristic	amyloid	deposits	
in	vessel	walls	in	AD	brain,	cerebral	amyloid	angiopathy		
Evidence	from	animal	models	implicates	complement	in	AD.	
Animal	models	have	been	both	a	blessing	and	a	curse	for	AD	research.	For	rare,	inherited	dementias,	
including	several	of	the	early-onset	forms	of	AD,	single	genes	have	been	implicated	and	here	animal	
models	replicating	the	genetic	change	and	(to	varying	degrees)	the	pathological	course	can	be	
generated	and	inform	understanding	[51].	For	the	much	more	common	late	onset	AD,	animal	
models	are	less	informative	and	often	misleading.	Late	onset	AD	is	genetically	complex	and	
represents	a	spectrum	of	disease,	not	a	single,	homogeneous	condition.	There	are	multiple	
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pathological	hallmarks,	including	but	not	restricted	to	the	classical	amyloid	plaques	and	tau	tangles,	
and	large	inter-individual	variability	in	pathological	changes	and	disease	course.	Despite	these	many	
issues,	a	huge	amount	of	work	has	been	performed	to	generate	and	characterise	rodent	models	of	
AD	that	replicate	some	of	the	pathological	and	clinical	aspects	of	the	disease	[52,53].	Evidence	from	
rodent	models	has	in	many	instances	informed	understanding	of	human	AD,	but	has	also	
occasionally	misled.			
Much	of	the	immuohistochemical	evidence	for	complement	dysregulation	noted	above	in	humans	
has	been	recapitulated	in	various	animal	models;	for	example,	in	a	PS1/APP	mouse	model	C1q	was	
co-localised	with	amyloid	plaques	[54].	Roles	of	complement	in	mouse	AD	models	have	been	tested	
either	using	complement-deficient	mice	or	administration	of	anti-complement	drugs.	The	resulting	
data	has	been	confusing	and	inconsistent,	reflecting	the	variability	in	models	noted	above	and	
reviewed	elsewhere	[55].	In	two	related	models,	Tg2576	and	APPPS1	(Tg2576	x	mutant	PS1),	both	
characterised	by	increased	Aβ	plaques,	activated	microglia	and	astrocytes	and	dystrophic	neurites,	
C1q	deficiency	was	strongly	protective,	supporting	a	role	for	classical	pathway	activation	[56].	In	
sharp	contrast,	in	a	related	APP-transgenic	(hAPP)	model,	C3	deficiency	was	associated	with	
increased	plaque	burden	and	neuronal	loss	in	aged	mice	[57].	In	support	of	this	latter	finding,	
inhibition	of	complement	activation	by	expression	of	the	C3	convertase	regulator	soluble	Crry	in	the	
brain	exacerbated	amyloid	plaque	formation	and	neuronal	degeneration	in	the	hAPP	model	[58].	
These	authors	first	showed	that	overproduction	of	TGF-β1	in	the	model	was	associated	with	
increased	microglial	activation,	reduced	plaque	load	and	elevated	C3	levels	in	brain.	Together,	these	
studies	were	interpreted	as	demonstrating	a	role	for	C3	in	the	clearance	of	plaques	and	
maintenance	of	neuronal	viability.	A	recent	study	testing	effects	of	C3	deficiency	in	the	APPPS1	
model	emphasised	the	dual-edged	nature	of	complement;	C3-deficient	mice	showed	an	increase	in	
amyloid	plaque	load,	in	agreement	with	other	studies,	but	were	nevertheless	protected	against	
cognitive	decline	[59].	There	were	fewer	plaque-associated	microglia	and	astrocytes,	and	
inflammatory	cytokine	levels	were	lower	in	brain,	suggesting	that	the	microglial	phenotype	was	
markedly	different	in	the	absence	of	C3.	
A	recent	report	linked	the	“housekeeping”	synaptic	processing	roles	of	complement	described	above	
with	complement	roles	in	AD.	In	the	hAPP	model,	C1q	labelling	of	synapses	was	seen	early	and	in	
much	higher	amounts	than	in	normal	mice;	inhibition	of	C1q	using	a	blocking	antibody	or	deficiency	
of	either	C1q	or	C3	reduced	synaptic	elimination	and	improved	hippocampal	function	[60].	Notably,	
blockade	of	CR3,	the	phagocytic	receptor	for	the	complement	opsonin	iC3b,	also	protected	synapses	
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in	the	model,	demonstrating	that	synaptic	removal	in	this	context	involved	a	collaboration	between	
complement	and	microglia.		
	
Genetics	implicates	complement	in	AD.		
The	most	convincing	evidence	that	complement	is	causatively	involved	in	AD	comes	from	genetics.		
The	most	significant	genetic	risk	factor	for	late-onset	AD	is	the	e4	allele	of	the	ApoE	lipoprotein;	this	
is	associated	with	increased	brain	amyloid	burden	through	mechanisms	that	remain	unclear.	Of	the	
handful	of	other	genes	linked	to	AD	in	recent	genome-wide	association	studies	(GWAS),	several	are	
complement-related	–	the	genes	encoding	clusterin	and	complement	receptor	1	(CR1)	were	linked	in	
first	studies	[61,62],	and	more	complement	genes	emerged	from	pathway	studies,	notably	the	genes	
encoding	C1s	and	C9	[63-65].	Precisely	how	these	complement	genes	and	pathways	link	to	AD	
pathogenesis	is	the	subject	of	intense	research	and	debate;	an	emerging	consensus	suggests	roles	in	
waste	disposal	and	inflammation	are	key.		
Clusterin,	also	known	as	ApoJ,	is	a	multifunctional	molecular	chaperone	that,	among	its	many	
activities,	is	a	fluid	phase	regulator	of	the	complement	terminal	pathway.		The	clusterin	(CLU)	gene	is	
the	third	most	associated	risk	gene	for	late	onset	AD.	In	GWAS,	three	single	nucleotide	
polymorphisms	(SNPs)	in	the	Clu	gene,	rs11136000	(intronic),	rs2279590	(intronic),	and	rs9331888	
(non-coding)	were	significantly	associated	with	AD	in	a	predominantly	Caucasian	cohort	[61,62].	All	
three	SNPs	are	non-coding/intronic	and	little	is	known	regarding	how	these	variants	impact	clusterin	
protein	or	the	development	of	AD	pathology.	Numerous	studies	have	addressed	roles	of	the	Clu	SNP	
in	Aβ	deposition	and	plaque	assembly,	neuronal	health	and	metabolism,	lipid	handling	and	effects	
on	brain	imaging	or	biomarkers.	All	three	SNPs	impacted	the	amount	of	Aβ	deposition,	while	the	
rs9331888	SNP	increased	rate	of	Aβ	deposition,	and	rs9331888	was	associated	with	hippocampus	
volume,	all	assessed	by	imaging	[66].	The	rs11136000	SNP	associated	with	CSF	Tau	levels	in	AD	
patients	[67].	These	authors	also	described	an	intracellular	form	of	clusterin	in	AD	model	mice	and	
humans,	showed	its	association	with	the	AD	risk	Clu	SNP	and	that	intracellular	clusterin	interacted	
with	another	GWAS	hit,	BIN1,	to	drive	Tau	pathology	in	AD,	thereby	identifying	a	pathway	that	
linked	two	genetic	associations.		
CR1	is	the	cell	surface	receptor	for	the	C3b	fragment;	CR1	on	erythrocytes	plays	important	roles	in	
immune	complex	transport	and	phagocytic	cell	expression	supports	phagocytosis	of	complement	
opsonised	particles	[68].	GWAS	identified	two	SNPs	associated	with	AD;	rs4844609,	a	coding	SNP	
that	causes	a	single	amino	acid	change	(T1610S)	in	the	26
th
	short	consensus	repeat	(SCR)	of	CR1,	a	
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region	reported	to	be	a	C1q	binding	site,	and	an	intronic	SNP,	rs6656401,	that	is	very	strongly	
associated	with	the	CR1	length	polymorphism	[62]	(Figure	3).	Increased	binding	affinity	for	C1q	has	
been	reported	for	the	risk	allele	of	rs4844609	[69].	The	long	form	of	CR1	(CR1*2)	that	is	associated	
with	the	risk	allele	at	the	rs6656401	SNP	differs	from	the	more	common	shorter	CR1*1	in	that	it	has	
acquired	an	additional	long	homologous	repeat	(LHR);	each	LHR	comprises	seven	SCRs,	each	
homologous	to	its	equivalent	in	the	other	LHRs.	CR1*1	extracellular	domain	comprises	4	LHRs	while	
CR1*2	comprises	5.		The	additional	LHR	adds	C3	fragment	binding	sites	so	can	be	considered	a	gain-
of-function;	however,	CR1*2	is	associated	with	a	lower	copy	number	of	CR1	on	erythrocytes	sites,	
and	perhaps	other	cells	[70].	Indeed,	it	has	been	suggested	that	reduced	CR1	expression	on	
erythrocytes	leading	to	impaired	amyloid	clearance	is	the	mechanism	by	which	the	rs6656401	SNP	
impacts	AD	pathology	[71].		
Screening	for	AD-associated	genes	in	a	large	Chinese	cohort	demonstrated	rather	weak	association	
with	the	most	significant	hits	in	the	Caucasian	analyses	and	identified	strong	associations	with	SNPs	
in	the	gene	encoding	the	complement	regulator	factor	H	(CFH);	the	two	strongest	associating	SNPs,	
rs1061170	and	rs800292,	are	both	coding	variants	causing	respectively	a	H402Y	and	a	I62V	change	in	
the	protein	[72]	(Figure	3).	In	both	cases,	the	risk	allele	was	associated	with	higher	atrophy	rate	and	
more	severe	cognitive	decline.		Of	note,	these	two	CFH	SNPs	have	previously	been	reported	as	
strong	risk	factors	for	age-related	macular	degeneration	in	diverse	cohorts	and	shown	to	affect	the	
complement	regulatory	activity	of	CFH	[73-75].	
Complement	biomarkers	and	AD.	
There	is	a	lack	of	informative	biomarkers	to	aid	diagnosis,	stratification,	or	prediction	of	outcome	in	
AD	or	that	predict	progression	from	mild	cognitive	impairment	(MCI)	to	AD.	Biomarkers	could	be	
measured	in	CSF	or	plasma;	however,	sampling	CSF	requires	lumbar	puncture	-	invasive	and	
potentially	dangerous	-	and	certainly	not	a	viable	option	for	a	screening	test	in	the	healthy	elderly.	A	
few	plasma	markers	have	been	described	but	are	untested	in	preclinical	disease	and	likely	unsuitable	
for	early	diagnosis	[76,77].	The	goal	for	current	studies	is	to	deliver	a	highly	informative	plasma	
biomarker	or	set	of	markers	that	enable	early	diagnosis	and	predict	disease	course.	If	complement	
dysregulation	is	a	feature	of	AD	then	measurement	of	complement	biomarkers	might	help	diagnose,	
predict	or	stratify	the	disease.	Among	the	complement	proteins	reported	to	be	associated	with	AD,	
CFH	and	clusterin,	both	implicated	from	genetics,	emerge	from	multiple	studies,	although	there	are	
conflicting	reports	that	do	not	support	these	associations.	Plasma	clusterin	levels	were	associated	
with	disease,	disease	subtype,	and	rate	of	progression	[78-80],	and	plasma	factor	I	(CFI)	levels	were	
predictive	of	brain	atrophy	[81].	
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We	measured	a	complement	marker	set	comprising	5	complement	proteins	and	4	activation	
products	in	plasma	from	MCI,	AD,	and	controls	[82].	Assessed	as	single	analytes,	only	clusterin	
differed	significantly	between	controls	and	AD	and	when	combined	with	relevant	co-variables	was	
highly	predictive	of	disease.	When	complement	analytes	were	measured	in	MCI,	3	(clusterin,	CFI,	
TCC)	were	different	between	those	who	a	year	later	had	converted	to	AD	and	those	who	did	not	
convert;	a	multivariate	model	based	on	these	analytes	was	highly	predictive	of	risk	of	progression	in	
MCI	individuals	who	had	converted	to	dementia	one	year	later	compared	to	non-converters;	a	
model	combining	these	three	analytes	was	highly	predictive	of	conversion	with	a	predictive	power	of	
85%	(Figure	4).	We	also	correlated	plasma	biomarkers	with	genetic	risk	of	AD	measured	using	a	
polygenic	score	that	took	account	of	all	known	genetic	risk	factors	[83].	The	strongest	association	
was	again	with	clusterin,	higher	levels	in	plasma	correlating	strongly	with	polygenic	score.	Our	
current	aim	is	to	develop	a	“best	set”	of	complement	and	other	inflammatory	markers	in	plasma	
that	can	be	used	to	build	multi-parameter	models	for	disease	prediction	and	stratification	for	
therapy	in	MCI	and	AD.	
Targeting	complement	in	AD.	
The	text	above	makes	the	case	that	complement	is	an	important	contributing	factor	to	inflammation	
and	neurodegeneration	in	AD.	Although	complement	may	not	be	the	primary	trigger	for	the	
pathology,	once	activated	it	is	a	powerful	driver	of	the	disease,	a	situation	exacerbated	by	the	
sensitivity	of	brain	cells	to	complement-mediated	damage.	However,	the	evidence	suggests	that	the	
situation	in	AD	is	more	complex	with	complement	also	having	beneficial	effects	by	limiting	the	
accumulation	of	debris,	an	activity	that	may	be	the	predominant	contribution	early	in	the	disease	
process.	Any	attempt	to	target	complement	activation	in	AD	must	take	account	of	this	complexity	
and	requires	signposts	from	biomarkers	or	imaging	to	identify	whether,	when	and	how	complement	
should	be	targeted.	The	first	two	of	these	considerations	await	clarification	from	biomarker	and	
imaging	studies;	I	will	here	focus	on	the	last	–	how	to	target	complement	dysregulation	in	the	AD	
brain.		
As	comprehensively	detailed	elsewhere	in	this	volume	(Harris	CL,	Expanding	horizons	in	complement	
drug	discovery:	challenges	and	emerging	strategies),	complement	therapeutics	is	undergoing	a	sea	
change	with	numerous	new	drugs	appearing	targeting	different	stages	and	effectors.	No	one	anti-
complement	agent	will	fit	all	disease	requirements	and	selection	of	an	appropriate	agent	requires	an	
understanding	of	the	nature	of	the	dysregulation	-	which	pathways	are	activated,	which	of	the	
activation	products	are	causing	damage	and	which	are	irrelevant	or	even	protective.	In	AD,	choice	of	
therapy	will	also	be	dictated	by	factors	such	as	ease	of	administration,	suitability	for	long-term	use,	
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safety	and,	of	course,	cost.	This	last	factor	is	of	particular	relevance	for	anti-complement	therapies	
since	currently	available	drugs	are	eye-wateringly	expensive	and	their	use	in	a	common,	chronic	
disease	like	AD	would	be	unaffordable	in	most	health	systems	[84].	Only	two	anti-complement	
agents	are	currently	licenced	for	use,	plasma-derived	C1	esterase	inhibitor	(C1INH;	Cinryze™;	
Berinert™)	and	the	C5-blocking	monoclonal	antibody	Eculizumab™.	C1INH	is	a	large	(~70kDa)	serine	
protease	inhibitor,	developed	for	treatment	of	hereditary	angioedema	and	untested	in	neurological	
diseases;	it	inhibits	the	complement	classical	pathway	by	dissociating	the	C1	complex.	Eculizumab,	
licensed	for	use	in	two	rare	non-CNS	conditions,	has	been	tested	in	a	small	trial	in	the	rare	
demyelinating	disease	neuromyelitis	optica	with	good	effect	[85].	Eculizumab	prevents	cleavage	of	
C5,	thus	stopping	generation	of	the	effectors	C5a	and	MAC.	Neither	of	these	agents	is	a	likely	
candidate	for	testing	in	AD,	primarily	because	they	will	not	cross	the	BBB.		
For	a	typical	monoclonal	antibody	or	other	large	protein	drug	administered	systemically,	brain	levels	
are	around	0.1%	of	those	in	the	blood,	making	it	essentially	impossible	to	get	enough	into	the	brain	
to	inhibit	a	relatively	abundant	complement	target.	Drug	delivery	then	becomes	the	biggest	barrier	
to	treating	AD.	To	circumvent	this	issue,	either	drugs	must	be	designed	that	are	BBB	permeant	
(generally	small,	lipophilic	entities)	or	“trojan	horse”	carrier	methods	must	be	used	[86]	(Figure	5).		
The	molecular	weight	threshold	for	effective	drug	delivery	across	the	BBB	is	~400Da	[87];	hence,	
most	drugs	labelled	as	“small	molecules”	will	not	readily	access	the	brain.	Lipid	solubility	inversely	
correlates	with	hydrogen	binding	capacity	because	more	hydrogen	bonds	translates	to	more	water-
binding,	effectively	increasing	the	molecular	weight	of	the	drug	[88].	Medicinal	chemistry	
approaches	to	create	BBB-penetrant	drugs	by	increasing	lipophilicity	have	met	with	mixed	success.	
Some	small	molecule	drugs	are	actively	transported	into	the	brain,	a	process	termed	carrier-
mediated	transport	(CMT);	for	example,	DOPA	used	in	Parkinson’s	disease.	There	are	numerous	CMT	
pathways	across	the	BBB,	offering	considerable	potential	for	drug	delivery.	For	larger	drugs	such	as	
antibodies,	receptor-mediated	transport	(RMT)	systems	can	be	exploited;	hijacking	brain	endothelial	
cell	transporter	receptors	for	insulin	or	transferrin	(Tf).	Much	effort	has	been	expended	to	modify	
anti-amyloid	antibodies	to	bind	these	receptors,	for	example	by	piggy-backing	onto	anti-receptor	
antibodies	[89].	Similar	approaches	have	been	used	to	deliver	TNF	inhibitory	proteins	for	therapy	of	
AD	[90]	(Figure	5).			
The	design	of	anti-complement	agents	for	efficient	delivery	to	the	brain	has	yet	to	begin.	Chimeric	
versions	of	Eculizumab	or	other	anti-complement	antibody	therapeutics	that	can	engage	RMT	
pathways	across	the	BBB	should	be	an	early	priority.	Annexon	Biosciences	
(http://www.annexonbio.com/science/)	have	developed	C1q-blocking	monoclonal	antibodies	
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(ANX005/007)	for	therapy	of	AD	but	have	not	yet	addressed	the	delivery	problem.	Another	anti-C1q	
antibody	was	neuroprotective	in	a	mouse	peripheral	neuropathy	model	[91].		Numerous	small	
molecule	anti-complement	drugs	targeting	complement	receptors	(for	example,	C5a	receptor	
antagonist	peptides;	[92]),	or	complement	enzymes	(for	example,	factor	D	blockers;	[93])	are	in	
development	and	approaching	the	clinic;	however,	to	date,	none	have	been	designed	with	BBB-
penetrance	in	mind.	This	is	a	crucial	gap	that	needs	to	be	closed	to	enable	targeting	of	complement	
dysregulation	in	the	brain	in	AD.		
Concluding	remarks.	
Over	the	last	decade	there	has	been	an	explosion	of	understanding	regarding	the	relevance	of	
inflammation	in	AD	and	other	neurodegenerative	diseases.	Alongside	this,	the	roles	played	by	the	
potent	pro-inflammatory	and	cytotoxic	system,	complement,	have	been	recognised.	Complement	
plays	complex	roles	in	brain	homeostasis,	and	likely	has	both	protective	and	exacerbating	effects	on	
disease.	Evidence	suggests	that	complement	restricts	amyloid	plaque	formation	and	aids	clearance	
of	plaque	components,	but	also	contributes	to	the	switch	of	microglia	and	astrocytes	into	activated	
neurotoxic	cells	that	drive	the	pathology	[94].	Given	this	complexity,	anti-complement	therapies	
need	to	be	given	to	the	right	patients,	at	the	right	time,	target	the	right	pathway	and	get	to	the	right	
place,	a	host	of	challenges	that	have	yet	to	be	addressed.	Biomarkers	and	imaging	to	stratify	and	
select	will	be	key	to	the	success	of	any	therapeutic	intervention,	though	perhaps	the	biggest	
challenge	is	to	create	anti-complement	drugs	that	are	brain-permeant	and	can	get	to	the	sites	of	
disease	even	in	the	early	stages.	Properly	constituted	clinical	trials	of	appropriate	anti-complement	
therapies	are	now	urgently	needed.	Evidence	to	date	suggests	that	agents	specifically	inhibiting	
classical	pathway	activation	might	be	most	appropriate,	although	C5a	antagonists	or	inhibitors	of	AP	
activation	might	also	be	useful	(and	perhaps	less	risky).		Protocols	to	monitor	systemic	and	central	
complement	inhibition	and	minimise	risk	of	infection	or	other	iatrogenic	effects	are	needed	to	
support	future	trials.	Despite	these	many	issues,	complement	represents	a	tractable	target	in	a	
currently	untreatable	disease.																		
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Figure	Legends	
Figure	1.	Complement	dysregulation	in	the	AD	brain.	Complement	(C)	may	access	the	brain	
parenchyma	from	plasma	through	a	disrupted	BBB	or	may	be	made	locally	by	glia	and/or	neurones.	
Complement	is	activated	(via	the	CP)	on	amyloid	plaques;	this	may	facilitate	opsonic	clearance	but	
also	drives	inflammatory	activation	of	glia	via	C5a	(and	C3a).	Activated	microglia	synthesise	
inflammatory	cytokines	and	more	complement	proteins,	stoking	the	flames.		Complement	activation	
on	neurones	and	oligodendrocytes	leads	directly	to	cell	damage	and	death.	Injured	and	dead	cells	
activate	more	complement,	leading	to	dysregulation,	further	inflammation	and	tissue	damage.			
Figure	2.	Complement	components	and	activation	products	in	the	AD	brain.	Examples	of	AD	brain	
sections	stained	with	different	complement	antibodies:	plaques	stain	strongly	for	C1q,	MAC	and	
CFH.	Neurones	are	also	strongly	positive	for	CFH.	Aβ40	staining	of	plaques	is	shown	as	a	control.			
Figure	3.	Association	of	SNPs	in	CR1	and	CFH	with	AD.	A.	The	short	(CR1*1)	and	long	(CR1*2)	
variants	of	CR1	are	illustrated,	differing	by	the	acquisition	of	an	extra	LHR	(LHR-S)	in	the	long	forms;	
CR1*2	is	strongly	associated	with	the	risk	allele	at	the	rs6656401	SNP.	Individual	SCRs	are	
represented	by	ovals.	Binding	sites	for	C3b,	C4b	and	CR1	are	indicated.	The	T1610S	(rs4844609)	
coding	SNP	in	the	26th	SCR	is	adjacent	the	C1q	binding	site	in	LHR-D.		B.	CFH	comprises	a	string	of	30	
SCRs.	Binding	sites	for	C3b,	C3d	and	glycosaminoglycans	(GAGs)	are	indicated.	The	two	coding	SNPs	
associated	with	AD	in	some	ethnic	groups	respectively	cause	single	amino	acid	changes	I62V	(at	the	
interface	of	SCRs	1	and	2	and	in	the	C3b	binding	site)	and	Y402H	(in	SCR	7	and	part	of	a	GAG	binding	
site).	
Figure	4.	Plasma	complement	biomarkers	predict	progression	in	mild	cognitive	impairment	(MCI).	
Results	of	a	multivariate	analysis	to	identify	the	best	plasma	complement	biomarkers	to	differentiate	
AD	from	controls	(A)	and	to	predict	progression	in	individuals	with	MCI	(B).	Only	clusterin	was	
significant	in	the	first	analysis;	with	ApoE	status	it	gave	a	predictive	power	(AUC)	of	0.78.	Clusterin,	
CFI	and	TCC	were	together	highly	predictive	of	progression	in	MCI	(AUC	of	0.85).	Modified	from	
Reference	82.		
Figure	5.	Getting	anti-complement	drugs	into	the	AD	brain.		Carrier-mediated	transport	(CMT)	
actively	delivers	some	small	molecule	drugs	into	the	brain	(1),	utilising	one	of	a	large	number	of	
intracellular	transporters.	A	small	molecule	anti-complement	drug	(illustrated	in	red)	could	be	
designed	to	engage	CMT	for	delivery	across	the	BBB.	For	larger	molecules,	“Trojan	Horse”	methods	
can	be	utilised	to	deliver,	hijacking	receptor-mediated	transport	(RMT)	systems.	Chimeric	antibodies	
capable	of	binding	a	relevant	receptor	(usually	either	the	transferrin	receptor	or	the	insulin	receptor)	
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through	one	arm	and	carrying	an	anti-complement	site	on	the	other	(in	red;	anti-C1q;	anti-C5	etc)	
will	be	transported	across	the	BBB	and	released	into	the	brain	parenchyma	to	inhibit	complement.	
Alternatively,	a	complement	regulator	can	be	coupled	recombinantly	or	chemically	to	the	anti-
receptor	antibody	(3),	allowing	it	to	piggy-back	across	the	BBB.		
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